Uniportal robotic-assisted thoracic surgery (U-RATS) represents a recent evolution in minimally invasive lung resection, combining the single-incision philosophy with robotic technology. However, its perioperative safety and outcomes have not been clearly defined across published studies. A systematic review and meta-analysis were conducted in accordance with PRISMA guidelines and a registered protocol. PubMed, Web of Science, and the Cochrane Library were searched for studies reporting perioperative outcomes of U-RATS for anatomic lung resection in adults. Primary outcomes included conversion rate, morbidity, and mortality. Secondary outcomes were operative time, estimated blood loss, length of hospital stay, and lymph node yield. Random-effects models were applied to pool estimates. Sixteen studies encompassing 579 patients were included. The pooled conversion rate was 1.34% (95% CI: 0.42–4.15%), with no observed heterogeneity. The pooled postoperative morbidity rate was 5.99% (95% CI: 4.46–7.91%), and the pooled mortality rate was 0.21% (95% CI: 0.07–0.64%). The pooled mean operative time was 171.3 min, the estimated blood loss was 51.9 mL, and the postoperative length of stay was 4.9 days. Across 11 studies, the pooled lymph node yield was 16.6 nodes (95% CI: 14.0–19.2; I² = 89.8%). Current evidence suggests that U-RATS is a safe and feasible approach for anatomic lung resection, with low conversion and complication rates and acceptable perioperative outcomes comparable to established minimally invasive techniques.
Adhesive small bowel obstruction (aSBO) is a common cause of emergency surgical admission, and the optimal initial management between early surgery and conservative non-operative management (NOM) remains debated, particularly regarding recurrence and short-term safety. This systematic review aimed to evaluate short- and long-term outcomes of early operative management compared with conservative treatment for aSBO in adult and paediatric populations. A systematic search of MEDLINE, Embase, Scopus, and Cochrane CENTRAL was conducted from inception to 2025 in accordance with PRISMA guidelines. Nine studies were included. In stable adults, NOM was generally safe with comparable short-term complication and mortality rates to early surgery; however, prolonged delays following NOM failure were associated with increased morbidity and bowel resection. Long-term outcomes consistently favoured early operative management, demonstrating a 40-60% relative reduction in recurrence. Water-soluble contrast protocols improved diagnostic accuracy and NOM success, while specific radiological findings predicted failure. In paediatric patients, NOM was effective in many cases, but infants under one year of age had a higher likelihood of requiring surgery, and delays beyond 48 hours increased bowel resection rates. Overall, NOM is safe for selected patients, but early surgery offers superior long-term recurrence outcomes.
adhesive small bowel obstructionearly surgical interventionconservative treatmentrecurrence
The Lancet Child & Adolescent Health · مجلد 10 (10) · 731-754
BACKGROUND: The Asia Pacific region is home to more than half of the world's 1·93 billion adolescents (aged 10-24 years). Addressing adolescent health in this region is of global importance, but to date a systematic analysis of key contributors to disease in adolescents has not been done, which is a barrier to responsive action. This systematic analysis of the Global Burden of Diseases, Injuries, and Risk Factors Study (GBD) 2023 aims to provide a comprehensive assessment of adolescent health across the Asia Pacific region, at both the subregional and national levels, encompassing burden of disease, mortality, and prevalence of adolescent risk factors. METHODS: As part of GBD 2023, we obtained estimates for cause-specific mortality, disability-adjusted life-years (DALYs), and risk factor prevalence by sex for adolescents aged 10-24 years and 5-year age groups (10-14 years, 15-19 years, and 20-24 years) across 44 countries and territories (hereafter referred to collectively as Asia Pacific), grouped by seven UN subregions, from 2000 to 2023. We extracted GBD 2023 population counts and estimates of number and rate (per 100 000 population) for mortality and disease burden (DALYs). Risk prevalence estimates were obtained directly from the Institute for Health Metrics and Evaluation, and binge drinking estimates were sourced from WHO. Estimates are reported with 95% uncertainty intervals (UIs) where possible. UIs were estimated by running 250 draws of the posterior distribution, ordering the draws, and selecting the 2·5th and 97·5th percentiles for each metric. FINDINGS: In 2023, in adolescents across Asia Pacific, there were 637 496 deaths and a total disease burden of 115·8 million DALYs, representing 34·1% of global adolescent deaths and 40·6% of the global adolescent burden of disease. Non-communicable diseases (NCDs; particularly mental disorders) were the leading causes of disease burden and mortality (64·8% of DALYs and 43·9% of deaths). Unintentional and transport injuries were also leading causes of death (14·7% of deaths due to transport injury and 13·3% of deaths due to unintentional injury) and leading causes of disease burden particularly among males in south-eastern Asia. In Melanesia, Micronesia, and some parts of south-eastern Asia (Cambodia, Indonesia, Laos, the Philippines, and Timor-Leste), respiratory infections and tuberculosis remained important contributors. Southern Asia had the largest reduction (1·5% per year) in all-cause DALYs over the study period, and Australia and New Zealand (0·2% per year) had the smallest, with females in Australia and New Zealand showing a slight increase contrary to regional trends. Eastern Asia had the largest reduction (2·8% per year) in all-cause mortality rate and Melanesia (0·8% per year) the smallest. Risk factors generally had between-subregion and within-subregion variation; however, some regional trends stood out, with overweight and obesity increasing in all countries across the region, and binge drinking increasing in more countries than not. In 2023, prevalence of smoking in males exceeded that in females in every country, from 40% difference in Timor-Leste to less than 1% difference in Australia. Anaemia prevalence is decreasing in all countries, but female prevalence was higher and reducing at a slower rate than in males. Bullying prevalence was slightly higher in Polynesia, Micronesia, and Melanesia combined, Australia and New Zealand, and eastern Asia compared with southern and south-eastern Asian subregions. INTERPRETATION: Several patterns were consistent across the region: the dominance of mental disorders and NCDs, the universal rise in overweight and obesity (particularly high in Oceanic countries but increasing rapidly in south and south-eastern Asia), and persistent sex-specific challenges across subregions: unintentional injuries and smoking in males, and anaemia in females. Actions to tackle shared risk factors (while accounting for context-specific local health profiles, workforce deficits, cultural factors, and health system capacity) should not be forgone due to local variation. Future research could focus on subnational variation, intersecting inequalities, and multi-sectoral interventions targeting shared risk factors. Priority actions should include regional investment in adolescent mental health services and obesity prevention, targeted injury reduction strategies for high-risk populations, and sex-specific approaches to smoking cessation and anaemia reduction, delivered through local health systems with the capacity and cultural responsiveness to meet local needs. FUNDING: Gates Foundation and Australian Government.
adolescent healthdisease burdenadolescent mortalitydisability-adjusted life years
Population Health Management · مجلد 29 (4) · 233-241
Atrial fibrillation (AF) is a highly prevalent comorbidity in patients with cardiomyopathy (CM), associated with worse cardiovascular outcomes. This study aims to provide a comprehensive, national-level analysis of AF and CM-related mortality in the United States. The Centers for Disease Control and Prevention Wide-Ranging Online Data for Epidemiologic Research database was utilized, using death certificates from 1999 to 2024. The study included patients aged ≥15 years with CM and AF. Statistical analyses were conducted to calculate age-adjusted mortality rates (AAMRs) per 100,000 individuals and annual percent changes with 95% confidence intervals (CIs). Between 1999 and 2024, CM with concomitant AF accounted for 134,470 deaths among individuals aged 15 years or older. The overall AAMR rose from 1.5 per 100,000 in 1999 to 2.3 in 2024. From 1999 to 2016, the AAMR rose modestly (1.5-1.8), followed by a pronounced rise from 2016 to 2022 (1.8-2.5), and a relative decline by 2024 (2.5-2.3). Compared with 2019, mortality in 2020 demonstrated a 15% relative increase (incidence rate ratio = 1.15; 95% CI: 1.11-1.19). Males had disproportionately higher AAMRs compared to females. By race, the highest AAMRs were observed in non-Hispanic (NH) Black and White populations (1.8 each). Regionally, the West and Midwest exhibited the highest AAMRs (1.9 each). Urban-rural stratification revealed higher AAMRs among rural areas (2.2) when compared with urban (1.8) areas. Targeted public-health interventions and resource allocation to address this growing cardiovascular mortality burden, particularly in high-risk demographic groups, are needed.
Frontiers in Microbiology · مجلد 16 · 1549044-1549044
Antimicrobial resistance (AMR) is recognized as one of the foremost global health challenges, complicating the treatment of infectious diseases and contributing to increased morbidity and mortality rates. Traditionally, microbiological culture and susceptibility testing methods, such as disk diffusion and minimum inhibitory concentration (MIC) assays, have been employed to identify AMR bacteria. However, these conventional techniques are often labor intensive and time consuming and lack the requisite sensitivity for the early detection of resistance. Recent advancements in molecular and genomic technologies-such as next-generation sequencing (NGS), matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS), lateral flow immunoassays (LFIAs), PCR-based diagnostic methods, and CRISPR-based diagnostics-have revolutionized the diagnosis of AMR. These innovative approaches provide increased sensitivity, reduced turnaround times, and the ability to identify genetic resistance mechanisms. This review seeks to examine the advantages and disadvantages of both emerging technologies and traditional methods for detecting AMR, emphasizing the potential benefits and limitations inherent to each. By understanding the strengths and limitations of these technologies, stakeholders, including researchers, healthcare professionals, regulatory agencies, health authorities, financial managers, and patients, can make informed decisions aimed at preventing the emergence and dissemination of antibiotic-resistant strains, thereby ultimately increasing patient safety.
antimicrobial resistanceantibiotic resistance detectionnext-generation sequencingMALDI-TOF mass spectrometry
Telehealth adoption gained popularity during the coronavirus disease 2019 (COVID-19) pandemic and had substantial and various impacts on patient outcomes depending on the specific environment, healthcare system, and quality of telehealth services supplied. Hence, this systematic review explored those impacts and their sustainability post-pandemic. To conduct this systematic review, a thorough literature search was undertaken in electronic databases such as PubMed, Medline, Web of Science, Google Scholar, databases, Embase, and PsycINFO using relevant keywords. We included articles written in English and published in the last 10 years that reported on the impact of telehealth adoption on various patient outcomes and the impact of sustainability post-pandemic. The findings of this systematic review highlight the remarkable impact of telehealth adoption on patient outcomes and the sustainability of these initiatives post-pandemic. Telehealth has proven to enhance various aspects of healthcare, spanning from prevention to follow-up. Another effect of telehealth adoption is the significant reduction in hospitalizations. Furthermore, telehealth profoundly impacts hospital stays, leading to a decrease in all-cause hospital days per patient by 1.07 (95% confidence interval (CI): 1.76 to 0.39) days and a shorter mean hospital stay for condition-related hospitalizations by 89% (95% CI 1.42 to 0.36), providing evidence of efficient healthcare delivery. There was also a reduction in mortality rates for patients receiving telemedicine interventions. Telehealth is also cost-effective while remaining highly effective. Patient satisfaction is another key outcome of telehealth adoption observed. The convenience and reduced expenses of telehealth have garnered positive feedback from patients, reinforcing the desirability of telehealth as a viable alternative to in-person visits. Despite these numerous benefits, barriers and disparities in telehealth adoption and utilization persist, especially in rural hospitals that face challenges, including a lack of Health Information Exchange (HIE) capacity, limited patient engagement capabilities, and the absence of financial reimbursement. This systematic review underscores the remarkable impact of telehealth adoption on patient outcomes and its sustainability post-pandemic. However, barriers and disparities still exist, requiring attention to ensure equitable access to telehealth services. The evidence supports the continued development and implementation of telehealth initiatives to improve healthcare delivery and patient outcomes post-pandemic.
The proliferation of multidrug-resistant, metallo-beta-lactamase-producing Klebsiella pneumoniae (MBL-producing K. pneumoniae) poses a major threat to public health resulting in increasing treatment costs, prolonged hospitalization, and mortality rate. Treating such bacteria presents substantial hurdles for clinicians. The combination of Aztreonam (ATM) and ceftazidime/avibactam (CAZ/AVI) is likely the most successful approach. The study evaluated the in vitro activity of CAZ/AVI in combination with ATM against MBL-producing K. pneumoniae clinical isolates collected from Suez Canal University Hospital patients. Carbapenem-resistant K. pneumoniae were isolated and identified from different specimens. The presence of metallo-β-lactamases was detected phenotypically by modified carbapenem inactivation method (mCIM) and EDTA-CIM (eCIM) testing, and genotypically for the three metallo-β-lactamase genes: blaNDM, blaIMP, and blaVIM by conventional PCR method. The synergistic effect of CAZ/AVI with ATM against MBL-producing K. pneumoniae was detected by ceftazidime-avibactam combination disks and E-test for antimicrobial susceptibility testing. Out of the 65 K. pneumoniae isolates recovered, 60% (39/65) were carbapenem-resistant (CRKP). According to the mCIM and eCIM tests, 89.7% (35/39) of CRKP isolates were carbapenemase-positive, and 68.6% (24/35) were metallo-β-lactamase (MBL)-positive. By using the conventional PCR, at least one of the MBL genes was present in each metallo-bata-lactamase-producing isolate: 8.3% carried the blaVIM gene, 66.7% the blaNDM, and 91.7% the blaIMP gene. After doing the disk combination method for ceftazidime-avibactam plus Aztreonam, 62.5% of the isolates shifted from resistance to sensitivity. Also, ceftazidime/avibactam plus Aztreonam resistance was reduced markedly among CRKP using the E-test. The addition of Aztreonam to ceftazidime/avibactam is an effective therapeutic option against MBL-producing K. pneumoniae.Clinical Trials Registry: Pan African Clinical Trials Registry. Trial No.: PACTR202410744344899. Trial URL: https://pactr.samrc.ac.za/TrialDisplay.aspx?TrialID=32000.
Congenital diaphragmatic hernia (CDH) is a rare but critical surgical disorder that can be managed using either open or thoracoscopic surgical approaches. However, the optimal approach remains a topic of debate. This study aimed to evaluate the efficacy and safety of thoracoscopic repair compared to open repair in patients with CDH. An extensive literature search was conducted across four databases (PubMed, Web of Science, Scopus, and Cochrane Library) from inception to May 2024, including all relevant studies comparing the two surgical modalities. Key outcomes assessed were hospital stay duration, operation time, mortality, and recurrence. Categorical outcomes were analyzed using the risk ratio (RR) with 95% confidence intervals (CI), while continuous outcomes were analyzed using the mean difference (MD) with 95% CI. Data analysis was performed using Review Manager (RevMan, Version 5.3). A total of 35 studies involving 1,680 individuals with CDH were included in our analysis. The pooled results revealed that thoracoscopic repair was associated with a shorter hospital stay (MD=-6.80, 95% CI [-9.39, -4.21], p< 0.0001) but a longer operation time (MD=23.30, 95% CI [7.22, 39.38], p=0.005) compared to the open approach. Additionally, thoracoscopic repair demonstrated lower mortality rates (RR=0.43, 95% CI [0.24, 0.76], p=0.004) but higher recurrence rates (RR=2.24, 95% CI [1.56, 3.21], p<0.0001) than open repair. Our findings suggest that thoracoscopic repair offers shorter hospital stays and lower mortality rates but involves longer operation times and higher recurrence rates compared to the open approach. These results highlight the need for further large, multicenter, randomized controlled trials to validate our findings and guide clinical decision-making.
congenital diaphragmatic herniathoracoscopic repairopen surgical repairminimally invasive surgery
European Journal of Clinical Investigation · مجلد 56 (1) · e70158-e70158
BACKGROUND: Elderly frailty is a multifaceted clinical condition with diminished physiological reserves and increased stress susceptibility. It increases disability, hospitalization and mortality rates, requiring multidomain therapy. Structured physical-activity-based medical treatment can reduce frailty in physical, mental and emotional areas. This assessment distinguishes outcomes among validated frailty models (phenotype-based vs. deficit-accumulation) to highlight model-specific effects. OBJECTIVES: The present systematic review assesses the efficacy of structured physical-activity-based physiotherapy in reducing frailty and enhancing physical, cognitive and emotional outcomes in persons aged ≥60. It highlights a critical data gap neglected by past studies by distinguishing intervention effects across proven frailty models (phenotype-based and deficit-accumulation frameworks). METHODOLOGY: The review used PRISMA criteria and the PICOS framework to find relevant papers published between January 2002 and December 2025. PubMed, Scopus, Cochrane Library and Embase were searched. RCTs and longitudinal cohort studies on physiotherapy or structured physical-activity therapies (e.g. resistance training, aerobic conditioning, balance exercises, multimodal programs) for individuals aged ≥60 years were eligible. Frailty, physical performance and quality of life were evaluated. Cochrane Risk of Bias 2.0 was used for randomised studies and ROBINS-I for non-randomised designs. RESULTS: 36 trials covered varied physiotherapy and structured physical-activity regimens. Participants, mostly aged ≥60, were mostly women (approximately two-thirds of the sample). The majority of investigations found that resistance training increased muscle strength and decreased frailty by 20%-35%. Exercises involving balance reduced fall risk by 25%-35%, while aerobic workouts improved gait and cardiovascular fitness. Multimodal interventions reversed frailty in 41%-50% of individuals and improved cognitive and emotional outcomes the highest. Physical performance, quality of life and functional independence improved across frailty models in weighted summaries. CONCLUSION: Structured physical-activity-based physiotherapy therapies, especially multimodal programs, reduce frailty and enhance physical, cognitive and emotional resilience in older persons, highlighting their value in comprehensive geriatric care.
Prehospital Emergency Care · مجلد 30 (6) · 795-803
OBJECTIVES: Sepsis is a life-threatening condition that results in significant morbidity and mortality, particularly when progressing to septic shock. Early detection and treatment, especially before hospital arrival, are crucial for improving outcomes. This review aimed to identify, assess, and summarize studies on the effectiveness of early detection methods and prehospital interventions in enhancing survival rates for patients with sepsis. METHODS: This descriptive systematic review followed the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols guidelines. A comprehensive literature search was conducted across six electronic databases to identify relevant studies published up to November 2024. Studies were screened and independently reviewed by four reviewers, and bias was assessed using the Cochrane Risk of Bias tool for randomized controlled trials (RCTs) and the Methodological Index for Non-Randomized Studies tool for observational studies. RESULTS: This review included 23 studies comprising 16,246 patients. Most of the studies were retrospective (57%), with RCTs (22%) and prospective observational studies (13%). Prehospital interventions-including antibiotic therapy (ABT), intravenous fluids, and norepinephrine-were associated with improved outcomes. Antibiotic therapy significantly reduced 30-day mortality. Norepinephrine improved survival, and early intravenous fluid administration lowered hospital mortality. The National Early Warning Score was superior to the quick Sequential Organ Failure Score in screening for sepsis (area under the receiver operating characteristic curve, 0.74 vs. 0.68). Emergency medical services (EMS) tools enhanced adherence to the 3-h sepsis bundle (80% vs. 44.2%). CONCLUSIONS: Early antibiotic administration, fluid resuscitation, and hemodynamic stabilization reduce mortality rates and improve clinical outcomes. Validated sepsis screening tools exhibit predictive utility and may support EMS protocols for earlier recognition, though evidence linking their use to improved outcomes remains limited.
Gastrointestinal (GI) tract diseases are among the most common diseases in the world, resulting in more than 8 million deaths. The majority of these deaths occur due to cancer or tumors. Early detection of these tumors can greatly lower the mortality rate. In this work, an implantable multiple-input-multiple-output (MIMO) antenna sensor is constructed for GI tract devices to detect the tumor. The implantable MIMO antenna sensor has two embedded antennas, each operating at 915 MHz. Both elements of the system are placed 0.6 mm apart from each other (edge-to-edge). The volume consumed by this design is measured to be 7 × 7 × 0.25 = 12.25 mm3. It occupies a very small volume due to miniaturization achieved using meandered resonating structures and a high-permittivity substrate. It maintains stable radiation performance (gain = −26.2 dBi at resonance). The antenna units are decoupled by maintaining a proper gap between them and adding a slot on the bottom side. An isolation level greater than 28.7 dB is achieved using these approaches. Since the MIMO system utilizes two antenna elements, its effectiveness is verified using MIMO parameters. At SNR = 20 dB, the channel capacity reaches 8.75 bps/Hz. The proposed antenna ensures high channel capacity and enables seamless communication while simultaneously acting as a sensor to monitor internal changes in the observed region. The frequency response change with variations in the permittivity of human tissue, enabling its sensing capability. Moreover, the antenna sensor maintains stable radiation and S-parameter performance throughout the sensing mechanism. Thus, the proposed solution is suitable for biomedical implants requiring both high-data-rate communication and sensing.
Background: Kyasanur forest disease virus (KFDV) remains a significant public health challenge due to the limitations of existing vaccines, creating a critical need for effective antiviral treatments. KFDV is a tick-borne virus responsible for 400-500 new cases annually, with a mortality rate of 3-5%. The nonstructural protein 1 (NS1), which plays crucial roles in host cell interactions, immune evasion, and viral replication, represents a promising target for antiviral drug development. Objective: This study aims to identify potential antiviral compounds that inhibit the activity of KFDV NS1 protein using a computational pharmacological drug design approach. The objectives include determining the 3D structure of the NS1 protein through homology modeling, conducting virtual screening of phytochemicals to identify potential inhibitors, and performing molecular dynamics simulations to assess the stability and binding free energies of the selected compounds. Methods: The 3D structure of KFDV NS1 protein was predicted using homology modeling and validated using Ramachandran plot analysis. Virtual screening of phytochemicals from the Indian Medicinal Plants, Phytochemistry And Therapeutics (IMPPAT) database was performed to identify potential NS1 inhibitors. The top 15 compounds with the highest binding affinities were selected and subjected to absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis. Molecular dynamics simulations were conducted in duplicates for 200 ns to evaluate the stability of the ligand-NS1 complexes, and an additional independent simulation with randomized initial velocities was performed to ensure statistical robustness. Binding free energies were calculated using the molecular mechanics-generalized born surface area (MM-GBSA) method to determine the binding strength of each compound. Results: The 3D structure of the KFDV NS1 protein was determined using I-Tasser-MTD, Robetta, and Swiss Model servers, and a minimized model of I-Tasser, achieving an ERRAT score of 94.37, was selected. Virtual screening of 11,530 phytochemicals from the IMPPAT database identified the top 115 compounds after three screening phases. Out of the 15 screened compounds, L2, L3, and L5 demonstrated notable binding affinities of -9.34, -9.12, and -9.08 kcal/mol, respectively, compared to the FDA-approved antiviral dasabuvir, which had a binding affinity of -8.0 kcal/mol. Molecular dynamics simulations confirmed the stability of compounds L2 (IMPHY010294), L3 (IMPHY001281), L5 (IMPHY011162), and dasabuvir, with free-energy binding values of -62.97 ± 4.0, -77.22 ± 4.71, -62.07 ± 2.88, and -87.68 ± 4.31 kcal/mol, respectively. Conclusion: findings.
Kyasanur forest disease virusNS1 proteinantiviral drug designphytochemicals
Abstract Background Pulmonary embolism (PE) continues to be a major contributor to mortality in the United States. Among the various risk factors associated with this life-threatening condition, atrial fibrillation (AF) stands as a significant contributor, further complicating the health challenges faced by patients. Purpose This study aims to uncover critical trends and regional disparities in mortality related to PE with concomitant AF across the United States from 1999 to 2020. Methods Death certificate data from the Centers for Disease Control and Prevention Wide-Ranging OnLine Data for Epidemiologic Research (CDC WONDER) database was to evaluate mortality associated with pulmonary embolism (PE) and atrial fibrillation/flutter (AF) from 1999 to 2020 for adults >15 years. Age-adjusted mortality rates (AAMRs) per 100,000 individuals, and Annual Percent Change (APCs) along with their 95% confidence intervals (CIs) were also calculated. Data were stratified by year, sex, race, and census region. Results PE with comorbid AF in adults aged ≥ 15 years resulted in 38,848 deaths, with an overall AAMR 0.70 (APC - 4.45; 95% CI: 3.94 – 4.96). The AAMR increased from 0.4 in 1999 to 0.8 in 2018 (APC: 4.2; 95% CI: 3.6 to 4.8), and further increased to 1.1 in 2020 (APC: 11.97; 95% CI: -7.3 – 35.2). Similar AAMR values were reported in both male and female in 1999 (AAMR: 0.4), however, men showed a slightly higher increase by 2020 (AAMR men: 1.4 vs women: 1.0). Non-Hispanic (NH) White adults had the highest overall AAMR (0.7), followed by NH Black (0.6), NH American Indian/Alaska Native (0.4), Hispanic or Latino (0.3), and NH Asian or Pacific Islander adults (0.2). AAMR did not vary substantially by region (overall AAMR: Midwest 0.7; South: 0.7; West: 0.7; Northeast: 0.6), and metropolitan areas had higher PE with comorbid AF-related AAMR (1.0) than nonmetropolitan areas (0.8). Wyoming, Colorado, and Vermont ranked in the top 90th percentile for PE with comorbid AF-related AAMR, with rates nearly four times higher than states in the lowest 10th percentile. Conclusion There’s been a steady increase in PE mortality with comorbid AF over the last 20 years. AAMR values were greater among non-Hispanic Adults, and those residing in metropolitan areas of the US. Notably, a sharper rise in AAMR post-2018 has been reported in both males and females. These findings highlight the importance of addressing and developing targeted interventions to curb the increased PE with comorbid AF mortality rates in the vulnerable population.
Acute kidney injury (AKI) is a devastating consequence of sepsis, accompanied by high mortality rates. It was suggested that inflammatory pathways are closely linked to the pathogenesis of lipopolysaccharide (LPS)-induced AKI. Inflammatory signaling, including PCSK9, HMGB1/RAGE/TLR4/MYD88/NF-κB, NLRP3/caspase-1 and Fractalkine/CX3CR1 are considered major forerunners in this link. Alirocumab, PCSK9 inhibitor, with remarkable anti-inflammatory features. Accordingly, this study aimed to elucidate the antibacterial effect of alirocumab against E. coli in vitro. Additionally, evaluation of the potential nephroprotective effects of alirocumab against LPS-induced AKI in rats, highlighting the potential underlying mechanisms involved in these beneficial actions. Thirty-six adult male Wistar rats were assorted into three groups (n=12). Group I; was a normal control group, whereas sepsis-mediated AKI was induced in groups II and III through single-dose intraperitoneal injection of LPS on day 16. In group III, animals were given alirocumab. The results revealed that LPS-induced AKI was mitigated by alirocumab, evidenced by amelioration in renal function tests (creatinine, cystatin C, KIM-1, and NGAL); oxidative stress biomarkers (Nrf2, HO-1, TAC, and MDA); apoptotic markers and renal histopathological findings. Besides, alirocumab pronouncedly hindered LPS-mediated inflammatory response, confirmed by diminishing HMGB1, TNF-α, IL-1β, and caspase-1 contents; the gene expression of PCSK9, RAGE, NF-ᴋB and Fractalkine/CX3CR1, along with mRNA expression of TLR4, MYD88, and NLRP3. Regarding the antibacterial actions, results showed that alirocumab displayed potential anti-bacterial activity against pathogenic gram-negative E. coli. In conclusion, alirocumab elicited nephroprotective activities against LPS-induced AKI via modulation of Nrf2/HO-1, PCSK9, HMGB1/RAGE/TLR4/MYD88/NF-ᴋB/NLRP3/Caspase-1, Fractalkine/CX3R1 and apoptotic axes.
Edge AI-based reinforcement learning is less reliant on mathematical models and relies on experience to help with the design and optimization of Consumer Technology models, making it ideal for learning dynamic treatment techniques. However, the current research still has the following problems: 1. The optimality of the learned strategy is considered without taking risks into account, leading to strategies with certain risks. 2. The issue of distribution shift is ignored, resulting in learned strategies that are completely different from those of doctors. 3. The patient’s historical observational data and treatments are ignored, making it difficult to accurately assess the patient’s state, which in turn leads to the inability to learn the optimal strategy. Based on this, we propose the DOSAC-DTR dynamic treatment strategy model, which integrates Dead-ends and offline monitoring into the Actor-Critic framework. First, we consider the risk of treatment actions recommended by the learned strategy and incorporate the concept of Dead-ends into the Actor-Critic framework. Second, to mitigate the distribution shift problem, we integrate physician monitoring into the Actor-Critic framework. This approach achieves better performance, resulting in lower estimated mortality rates and higher Jaccard index scores.